Transarteriyel Radyoembolizasyon

Ballı HT, Aikimbaev K. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety. Diagn Interv Radiol. 2020;26(5):482-7. doi:10.5152/dir.2020.19410.
Pieper CC, Meyer C, Wilhelm KE, et al. Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience. J Vasc Interv Radiol. 2016;27(9):1305-15.
Chang J, Charalel R, Noda C, et al. Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization. Anticancer Res. 2018;38(5):3063-8.
Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851-67. doi:10.1007/s00270-021-02968-1.
Arndt L, Villalobos A, Wagstaff W, et al. Evaluation of Medium-Term Efficacy of Y90 Radiation Segmentectomy vs Percutaneous Microwave Ablation in Patients with Solitary Surgically Unresectable < 4 cm Hepatocellular Carcinoma: A Propensity Score Matched Study. Cardiovasc Intervent Radiol. 2021;44(3):401-13.
Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. Cardiovasc Intervent Radiol. 2020;43(9):1305-14.
Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Br J Cancer. 2016;115(3):297-302.
Braat AJAT, Ahmadzadehfar H, Kappadath SC, et al. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. Cardiovasc Intervent Radiol. 2020;43(2):246-53.
Das A, Riaz A, Gabr A, et al. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. Eur J Nucl Med Mol Imaging. 2020;47(4):807-15.
Ebbers SC, Kunnen B, van Nierop BJ, et al. Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres. Cardiovasc Intervent Radiol. 2020;43(9):1378-83.
Ezponda A, Rodríguez-Fraile M, Morales M, Vivas I, De La Torre M, Sangro B, Bilbao JI. Hepatic Flow Redistribution is Feasible in Patients with Hepatic Malignancies Undergoing Same-Day Work-Up Angiography and Yttrium-90 Microsphere Radioembolization. Cardiovasc Intervent Radiol. 2020;43(7):987-95.
Gaba RC, Vanmiddlesworth KA. Chemoembolic hepatopulmonary shunt reduction to allow safe yttrium-90 radioembolization lobectomy of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35(6):1505-11.
Girardet R, Boughdad S, Digklia A, et al. Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium. Cardiovasc Intervent Radiol. 2020;43(11):1712-5.
Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68(4):1429-40.
Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol. 2021;27(43):7462-79. doi:10.3748/wjg.v27.i43.7462.
Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol. 2006;23(1):64-72.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. doi:10.1016/j.jhep.2021.11.018
Kwok N, Irani Z, Sheth R, Arellano RS. Hepatopulmonary shunt reduction with bland embolization for yttrium-90 radioembolization. Diagn Interv Imaging. 2016;97(3):369-70.
Loffroy R, Ronot M, Greget M, et al. Principal Investigators. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Cardiovasc Intervent Radiol. 2021;44(1):36-49.
Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers (Basel). 2020;12(7):1914. doi:10.3390/cancers12071914
Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151(6):1155-63.
Rafi S, Piduru SM, El-Rayes B, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440-8.
Bargellini I, Lorenzoni G, Cervelli R, Boni G, Cioni R. The Efficacy of Coil Embolization to Obtain Intrahepatic Redistribution in Radioembolization: Qualitative and Quantitative Analyses. Cardiovasc Intervent Radiol. 2020;43(11):1733-4.
Townsend A, Price TJ, Patterson K, Pittman K. Fluorouracil-induced hepatic artery spasm preventing yttrium-90 microsphere administration. Clin Nucl Med. 2008;33(8):528-30.
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47:2-6.
Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the uSA. Curr Gastroenterol Rep. 2019;21(4):17.
Wang CY, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore). 2019;98(4):e14070.
Xu Z, Xie H, Zhou L, Chen X, Zheng S. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma. Anal Cell Pathol (Amst). 2019:8619096. doi: 10.1155/2019/8619096.
Crocetti L, de Baére T, Pereira PL, Tarantino FP. CIRSE standards of practice on thermal ablation of liver tumours. Cardiovasc Intervent Radiol. 2020;43(7):951-62. doi:10.1007/s00270-020-02471-z.
Shi F, Tan Z, An H, Wang X, Xu Y, Wang S. Hepatocellular carcinoma ≤ 4 cm treated with radiofrequency ablation with or without percutaneous ethanol injection. Ann Hepatol. 2016;15(1):61-70. doi:10.5604/16652681.1184219.
Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology. 2017;65(6):1979-90. doi:10.1002/hep.29098.
Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99-105.
Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018;11:7315-21.
Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41:120-7.
Gordon AC, Gradishar WJ, Kaklamani VG, et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol. 2014;25(10):1523-32.
Niessen C, Thumann S, Beyer L, et al. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:43687. doi: 10.1038/srep43687.